IDEXX Laboratories price to free cash flow IDXX

Market value divided by free cash flow over the last twelve months, since 2011.

Today, Oct 23, 2026: 35.2×
10-year median: 63.2×
Against its 10-year history: 2nd; percentile: 0 is its lowest day, 100 its highest
10-year range: 31.7× to 106×
Peer median: 30.7×

IDEXX Laboratories' price to free cash flow is 35.2× as of Oct 23, 2026.

That is below its ten-year median of 63.2×, lower than on 98% of days in the last ten years.

Over that time it ranged from 31.7× in Sep 2026 to 106× in Jul 2020.

The median for 10 diagnostics and research stocks of a similar size is 30.7×.

Price to free cash flow over time

median 63.2×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	35.2×	31.7×	59.3×
2025	57.1×	39.3×	67.1×
2024	42.9×	42.6×	69.9×
2023	67.8×	52.4×	105×
2022	75.4×	44.8×	81.6×
2021	84.3×	67.8×	98.2×
2020	95.6×	51.4×	106×
2019	76.2×	57.1×	90.9×
2018	56.7×	51.3×	73.7×
2017	48.2×	43.7×	54.2×
2016	43.3×	39.2×	76.7×
2015	78.7×	32.6×	78.8×
2014	32.9×	29.1×	39.2×
2013	31.9×	27.9×	35.1×
2012	32.4×	27.4×	35.4×
2011	26.6×	24.0×	34.2×

Against its peers

Companies in Medical - Diagnostics & Research nearest IDEXX Laboratories' size, closest first, today.

Company	Price to free cash flow
IDXXIDEXX Laboratories	35.2×
WATWaters	112×
IQVIQVIA	21.1×
ILMNIllumina	43.7×
AAgilent Technologies	38.5×
MTDMettler-Toledo International	38.7×
DGXQuest Diagnostics	19.8×
LHLabcorp	23.1×
MEDPMedpace	26.4×
RVTYRevvity	31.7×
DHRDanaher	29.6×
Peer median	30.7×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on IDEXX Laboratories

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.